Article Text

Download PDFPDF
Clinicopathological concordance and discordance in three monozygotic twin pairs with familial Alzheimer’s disease
  1. Kiri L Brickell1,2,4,
  2. James B Leverenz2,4,
  3. Ellen J Steinbart2,4,
  4. Malia Rumbaugh4,
  5. Gerard D Schellenberg2,4,
  6. David Nochlin3,
  7. Thomas H Lampe4,
  8. Ida E Holm5,
  9. Vivianna Van Deerlin6,
  10. Wuxing Yuan6,
  11. Thomas D Bird2,4
  1. 1
    Neurological Foundation of New Zealand, New Zealand
  2. 2
    Departments of Neurology and Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA
  3. 3
    JFK Medical Center, Edison, New Jersey, USA
  4. 4
    GRECC, MIRECC, PADRECC, VA Puget Sound Health Care System, Seattle and Tacoma, Washington, USA
  5. 5
    Department of Pathology, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark
  6. 6
    Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, University of Pennsylvania Health System, Philadelphia, USA
  1. Dr Thomas D Bird, 182-GRECC, VA Puget Sound Health Care System, 1660 S Columbian Way, Seattle, WA 98108, USA; tomnroz{at}u.washington.edu

Abstract

Aim: Neuropathological examination of both individuals in a monozygotic (MZ) twin pair with Alzheimer’s disease (AD) is rare, especially in the molecular genetic era. We had the opportunity to assess the concordance and discordance of clinical presentation and neuropathology in three MZ twin pairs with AD.

Methods: The MZ twins were identified and characterised by the University of Washington Alzheimer’s Disease Research Center. We reviewed the available clinical and neuropathological records for all six cases looking specifically for concordance and discordance of clinical phenotype, neuritic amyloid plaques (NP), neurofibrillary tangles (NFT) and Lewy related pathology (LRP).

Results: Discordance in age of onset for developing AD in the MZ twins varied from 4 to 18 years. Clinical presentations also differed between twins. One twin presented with a dementia with Lewy Body clinical syndrome while the other presented with typical clinical AD. Neuropathology within the MZ twin pairs was concordant for NP and NFT, regardless of duration of disease, and was discordant for LRP. This difference was most marked in the late onset AD twin pair. One pair was found to have a mutation in presenilin-1 (PS1) (A79V) with remarkably late onset in a family member.

Conclusions: MZ twins with AD can vary considerably in age of onset, presentation and disease duration. The concordance of NP and NFT pathological change and the discordance of LRP support the concept that, in AD, the former are primarily under genetic control whereas the latter (LRP) is more influenced by disease duration and environmental factors. The A79V mutation in PS1 can be associated with very late onset of dementia.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Supported by NIA/NIH grant No P50 AG 005136-22 and AG17586, Veterans Affairs research funds, and the Neurological Foundation of New Zealand.

  • Competing interests: None.

  • Abbreviations:
    AD
    Alzheimer’s disease
    EOAD
    early onset Alzheimer’s disease
    LOAD
    late onset Alzheimer’s disease
    LRP
    Lewy related pathology
    MZ
    monozygotic
    NFT
    neurofibrillary tangles
    NP
    neuritic amyloid plaques
    PS1
    presenilin 1
    PS2
    presenilin 2
    SNCA
    alpha-synuclein

Linked Articles